title: Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(A)anthracene-induced mammary carcinoma in the rat.
abstract: Although treatment with dehydroepiandrosterone (DHEA) and the antiestrogen EM-800 alone decreased dimethylbenz(A)anthracene (DMBA)-induced mammary tumor incidence from 95% to 57% and 38%, respectively, approximately 9 months after DMBA administration, only two tumors developed in the group of animals that received the combination of DHEA and EM-800, and these two tumors disappeared before the end of the experiment (P < 0.01 vs. DHEA or EM-800 alone). Average tumor number per tumor-bearing animal as well as average tumor area per tumor-bearing animal were further decreased in animals that received the combination therapy compared with the effect of each treatment alone (P < 0.01). DHEA induced 6.9% (P < 0.01), 10.6% (P < 0.05), and 8.2% (P < 0.01) increases in bone mineral density of total skeleton, lumbar spine, and femur, respectively. The addition of EM-800 to DHEA did not affect the enhancing effect of DHEA on bone mass. The combination of the two drugs had important inhibitory effects on the urinary excretion of calcium and phosphorus as well as on the urinary hydroxyproline/creatinine ratio. Serum total alkaline phosphatase was stimulated by DHEA. Treatment with EM-800 decreased both serum triglyceride and cholesterol levels, whereas DHEA had an inhibitory effect on serum triglycerides. Although treatment with EM-800 caused a marked atrophy of the mammary gland, DHEA alone reduced lobular hyperplasia seen in aged intact rats while causing an androgen-specific stimulation of the same structures in animals already receiving the antiestrogen EM-800. The combination of DHEA and EM-800 lowered ovarian weight by 24% (P < 0.01) and decreased serum estradiol concentrations to intact control levels, whereas each compound alone had no effect on ovarian weight and stimulated serum estradiol levels by 45% (P < 0.05) and 46% (P < 0.05), respectively. Treatment with EM-800 caused a marked inhibition of uterine and vaginal weight. The present data show the additive inhibitory effects of DHEA and EM-800 on the development of DMBA-induced mammary carcinoma in the rat, thus suggesting the potential benefits of such a combination for the prevention of breast cancer in women while preserving or even increasing bone mass and maintaining a favorable lipid profile.
authors.affiliation: Medical Research Council Group in Molecular Endocrinology, CHUL Research Center and Laval University, Québec, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Luo
authors.forename: A
authors.initials: A
authors.lastname: Sourla
authors.forename: C
authors.initials: C
authors.lastname: Labrie
authors.forename: A
authors.initials: A
authors.lastname: Bélanger
authors.forename: F
authors.initials: F
authors.lastname: Labrie
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene / Q000009:adverse effects; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D001578:Benzopyrans / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D002118:Calcium / Q000652:urine; D002273:Carcinogens / Q000009:adverse effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000473:pathology; D003687:Dehydroepiandrosterone / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000097:blood; D004965:Estrogen Antagonists / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005836:Genitalia, Female / Q000187:drug effects / Q000473:pathology; D008055:Lipids / Q000097:blood*; D007986:Luteinizing Hormone / Q000097:blood; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology*; D009929:Organ Size; D010758:Phosphorus / Q000652:urine; D011388:Prolactin / Q000097:blood; D011422:Propionates / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D001578:Benzopyrans; D002273:Carcinogens; D004965:Estrogen Antagonists; D008055:Lipids; D011422:Propionates; D010758:Phosphorus; D003687:Dehydroepiandrosterone; D004958:Estradiol; D015127:9,10-Dimethyl-1,2-benzanthracene; D011388:Prolactin; D007986:Luteinizing Hormone; D000469:Alkaline Phosphatase; D002118:Calcium; C106945:EM 800